Innovation Ventures Philanthropy Fund (InVent Fund)

Adam Abate, Ph.D. - Abate Labs

Invest in Ourselves

…the UCSF InVent Fund is open for business!

As part of our public mission, UCSF strives to translate our scientific discoveries for public benefit. Whether it is a new drug molecule, diagnostic, medical device, platform technology, or digital health application, our goal is to ensure the best new therapies and technologies can make their way to patients as efficiently and safely as possible. To that end, Innovation Ventures supports faculty whose inventions would benefit from licensing to new or established companies with the expertise and funding to develop those further. However, for projects that would benefit from some additional internal funding that could result in compelling proof of concept or otherwise demonstrate transformative promise, UCSF has created the philanthropic “InVent Fund” to provide not only funding but access to experienced development expertise from within and around the UCSF community.

The program is described in greater detail along with a simple, on-line application. Just click the application button below. 

Application Information

Please note that applications for this initial round of submissions has concluded. Awardees can expecte to be announced by mid-November, 2019.

For follow-up questions directly related to the fund, please click "Contact" below. 


To learn about how you can support the Innovation Ventures Philanthropy Fund, please contact:

Michael J. Faber
Associate Vice Chancellor
University Development & Alumni Relations
University of California, San Francisco
Phone: 415-476-2617
Email: [email protected]

What We Do

  • Translational Funding
  • Technology Development

Our Team

  • Barry Selick, PhD

    Vice Chancellor, Business Development, Innovation and Partnerships

    Prior to joining UCSF, Barry was the CEO of Threshold Pharmaceuticals, a fully integrated oncology drug discovery/clinical development company that he led as CEO from its Series A financing through IPO to its eventual sale in 2017. He was also a Venture Partner at Sofinnova Ventures from June 2002 until July 2007. Prior to Threshold, Barry co-founded and was CEO and Chairman of Camitro, a venture capital backed drug discovery technology...

    Read more